Foresite Capital

Foresite Capital is a prominent multi-stage healthcare and life sciences investment firm based in San Francisco, United States. With approximately $10 billion in assets under management (AUM), the firm is a significant player in the biotech and health tech sectors. Foresite Capital's investment thesis centers on identifying and supporting innovative companies across therapeutics, life science tools, diagnostics, and digital health, aiming to drive advancements that address critical unmet medical needs.

The firm employs a flexible investment strategy, engaging with companies from their earliest stages of formation through to public market listings. While they participate across the entire lifecycle, Foresite Capital is particularly known for leading substantial growth equity rounds. Their typical first cheque for a significant investment generally ranges from $20 million to $100 million, reflecting their commitment to providing substantial capital to fuel company growth and development. This multi-stage approach allows them to build long-term relationships with portfolio companies, offering strategic guidance and operational support alongside financial backing.

Foresite Capital continues to demonstrate strong fundraising capabilities, exemplified by the closing of Foresite Capital Fund VI at $1.7 billion in 2022. This substantial capital pool further solidifies their capacity to make impactful investments in the evolving healthcare landscape. The firm's deep expertise in the life sciences, combined with its robust financial resources, positions it as a key partner for entrepreneurs and companies striving to bring transformative healthcare solutions to market.